About the Uterine Sarcoma Session
Uterine sarcoma, a rare form of cancer, originates in the muscles or other supporting tissues of the uterus. Despite its rarity compared to other uterine cancers like endometrial carcinoma, its aggressive nature poses significant challenges in diagnosis and treatment. Research in this field focuses on understanding its molecular mechanisms, identifying biomarkers for early detection, and developing targeted therapies to improve patient outcomes. Recent advancements in genomic profiling have shed light on the genomic landscape of uterine sarcoma, aiding in the discovery of potential therapeutic targets. However, due to its low incidence, clinical trials are limited, emphasizing the importance of collaborative efforts among researchers, clinicians, and patients to advance our understanding and management of this challenging disease.
Topics Covered in Uterine Sarcoma
Leiomyosarcoma
Endometrial Stromal Sarcoma
Adenosarcoma
Fibroid vs Sarcoma
Morcellation Risk
Hormonal Therapy
Related Scientific Sessions at CIOC 2027
Why Attend the Uterine Sarcoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Uterine Sarcoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Uterine Sarcoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Uterine Sarcoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Uterine Sarcoma Conference 2027 — FAQs
What is the Uterine Sarcoma track at CIOC 2027?
The Uterine Sarcoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Uterine Sarcoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Uterine Sarcoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Uterine Sarcoma are all welcome — whether presenting or attending.
Can I present my research in the Uterine Sarcoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Uterine Sarcoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Uterine Sarcoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.